BIOPHARMA CREDIT PLC
(THE "COMPANY")
RESULT OF 2024 ANNUAL GENERAL MEETING
The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed by way of a poll.
|
Resolutions |
Votes For |
% |
Votes Against |
% |
Total Votes |
% of Total Voting Rights Voted |
Votes Withheld1 |
|
1: To receive and accept the annual report and financial statements |
558,898,973 |
99.99% |
52,892 |
0.01% |
558,951,865 |
45.85% |
28,112 |
|
2: To approve the Directors' Remuneration Report |
558,576,994 |
99.97% |
177,879 |
0.03% |
558,754,873 |
45.83% |
225,104 |
|
3: To receive and approve the Directors' Remuneration Policy |
558,551,021 |
99.96% |
227,616 |
0.04% |
558,778,637 |
45.84% |
201,340 |
|
4: To re-elect Harry Hyman as a Director |
494,888,417 |
99.99% |
66,478 |
0.01% |
494,954,895 |
40.60% |
64,025,082 |
|
5: To re-elect Colin Bond as a Director |
558,759,159 |
99.99% |
76,104 |
0.01% |
558,835,263 |
45.84% |
144,714 |
|
6: To re-elect Duncan Budge as a Director |
494,888,417 |
88.56% |
63,946,846 |
11.44% |
558,835,263 |
45.84% |
144,714 |
|
7: To re-elect Stephanie Léouzon as a Director |
558,780,785 |
99.99% |
54,478 |
0.01% |
558,835,263 |
45.84% |
144,714 |
|
8: To re-elect Sapna Shah as a Director |
558,780,762 |
99.99% |
54,478 |
0.01% |
558,835,240 |
45.84% |
144,737 |
|
9: To re-elect Rolf Soderstrom as a Director |
558,744,159 |
99.99% |
76,104 |
0.01% |
558,820,263 |
45.84% |
159,714 |
|
10: To re-appoint Ernst & Young LLP as Auditor to the Company |
558,682,815 |
99.96% |
204,636 |
0.04% |
558,887,451 |
45.84% |
92,526 |
|
11: To authorise the Directors to determine the remuneration of the Auditor |
558,769,161 |
99.99% |
69,478 |
0.01% |
558,838,639 |
45.84% |
141,338 |
|
12: To approve the Company's dividend payment policy |
558,978,176 |
100.00% |
1,801 |
0.00% |
558,979,977 |
45.85% |
0 |
|
13: To authorise the allotment of shares by the Company |
556,785,857 |
99.62% |
2,150,350 |
0.38% |
558,936,207 |
45.85% |
43,770 |
|
14: To authorise the disapplication of pre-emption rights |
556,858,554 |
99.63% |
2,077,653 |
0.37% |
558,936,207 |
45.85% |
43,770 |
|
15: To authorise the Company to make market purchases of ordinary shares |
558,895,163 |
99.98% |
84,814 |
0.02% |
558,979,977 |
45.85% |
0 |
|
16: To authorise the Company to hold general meetings on 14 clear days' notice |
558,867,851 |
99.98% |
99,598 |
0.02% |
558,967,449 |
45.85% |
12,528 |
1. A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.
Copies of resolutions 13 to 16 have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
12 June 2024
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
T. +44 (0) 333 300 1950
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0) 20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
